Compare Crispr Therapeutics AG (CRSP) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Public Storage — how do they compare? Crispr Therapeutics AG trades at $50.46 (market cap $4.97B), while Public Storage trades at $317.25 (market cap $56.00B). The key difference: Public Storage is far larger — about 11.3× Crispr Therapeutics AG's market cap, and Public Storage pays a 3.76% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PSA | |
|---|---|---|
Market Cap | $4.97B | $56.00B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $329.64 |
52-Week Low | $44.34 | $258.44 |
Enterprise Value | $3.32B | $70.25B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Public Storage (PSA) trades at $321.86, up 0.41% on the day, with a neutral technical signal and strong profitability metrics including a 39.16% net income margin and 33.78% ROE. Recent earnings beats and the pending acquisition of National Storage Affiliates highlight strategic growth initiatives, supported by a $3.00 dividend and robust cash flow from operations of $3.19B in 2025.
The outlook is positive with a consensus price target of $332.25, though elevated valuation ratios (P/E 33.25) and integration risks from acquisitions pose challenges. Earnings growth and market expansion into Canada are key catalysts, while interest rate sensitivity and competitive pressures remain watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
